Navigation Links
InterMune Reports Second Quarter 2014 Financial Results and Business Highlights
Date:8/6/2014

s and our anti-fibrotic research programs."

Recent Business and Clinical Development Highlights

  • On July 17, 2014, InterMune reported that pirfenidone had been granted Breakthrough Therapy Designation by the FDA.  This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.  According to the FDA Fact Sheet: "If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug."
  • InterMune today reported that the FDA has informed the company that at this time, the agency does not plan to convene an advisory committee for pirfenidone.
  • On July 10, 2014, InterMune submitted to the European Medicines Agency (EMA) a variation to the Esbriet marketing authorization.  The purpose of the variation is to update the Summary of Product Characteristics (SmPC) to include the ASCEND clinical data.  InterMune anticipates receiving a decision on the proposed variation from the EMA in early 2015. 
  • At the International Conference of the American Thoracic Society (ATS) in May 2014, data from the Phase 3 ASCEND trial of pirfenidone in IPF were presented.  The ATS presentation included data and additional supportive analyses demonstrating the treatment effect of pirfenidone on Forced Vital Capacity (FVC) change and other important clinical endpoints, including mortality.  Additionally, the data demonstrated a favorable safety and tolerability profile of pirfenidone in ASCEND that was generally consistent with observations from the previous Phase 3 CAPACITY studies, open-label extension studies and post-marketing experience.  Simultaneous with its presentation at ATS, the results of ASCEND were published in the New England Journal o
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
    2. InterMune Announces Proposed Public Offering of Common Stock
    3. InterMune Reports Second Quarter 2013 Financial Results And Business Highlights
    4. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
    5. InterMune Announces Presentations of New Research in IPF at ERS
    6. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
    7. InterMune to Divest Actimmune® (Interferon Gamma-1b)
    8. Neurocrine Biosciences Reports Second Quarter 2014 Results
    9. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015
    10. China Biologic Reports Financial Results for the Second Quarter of 2014
    11. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... -- The Physician-Patient Alliance for Health & Safety ... "Surviving Your Hospital Stay: Physician-Patient Alliance for Health ... A sentence was omitted from the release. ... is a member of the National Coalition to Promote ... the National Coalition to Promote Continuous Monitoring of Patients ...
    (Date:7/31/2015)... LONDON , July 31, 2015 ... to decades of experience, the domestic pharmaceutical industry is ... today manufacture products to high international standards. ... well known is in sub-Saharan Africa: Morocco has quietly ... after South Africa . Indeed, Moroccan ...
    (Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
    Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
    ... Final results from,a 24-week study presented today at ... olanzapine long-acting injection (LAI),therapeutic doses showed a maintenance ... review of pooled safety data from all olanzapine ... Olanzapine LAI is an investigational formulation that ...
    ... 2 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the signature of ... de Lausanne (EPFL), aimed at the identification ... with pathways controlling cell fate,specification. The project, ...
    Cached Medicine Technology:Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 2Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 3Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 4Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 5Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 6Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 7Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 8Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 9Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment 2
    (Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... to clarify, edit and delete any message including ones already sent. , While text ...
    (Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
    (Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
    (Date:7/31/2015)... ... July 31, 2015 , ... According to an article published July ... they could reach a consensus on the steps that need to be taken to ... reached 90 percent consensus on a series of steps that each surgeon must complete ...
    Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
    ... ... refusing travellers with symptoms similar to flu to board planes, travel insurers are treating swine ... ... AA Travel Insurance are now enquiries from travellers concerned about whether they are covered if ...
    ... who struggle with CPAP treatment for obstructive sleep apnea ... the upper airway, because it holds the same quality-of-life ... in new research published in the August 2009 edition ... positive airway pressure (CPAP) therapy is a highly effective ...
    ... Speaker Nancy Pelosi issued the following statement tonight on the vote ... Affordable Health Choices Act, the third House committee to pass the ... Education and Labor Committee approved the bill earlier this month: ... have tried as a nation to make quality, affordable health insurance ...
    ... for people living with AIDS and increases with increasing ... 31 in the Journal of the National Cancer ... is known to be higher among people with AIDS, ... is unclear. Anil K. Chaturvedi, Ph.D., of the ...
    ... , NEW YORK, July 31 BBV Vietnam ... "Company") announced today that it has signed a non-binding letter of ... Pursuant to the provisions of the Company,s Articles of Incorporation, the ... combination. If the Company is unable to complete the business combination ...
    ... more health and social issues years later , FRIDAY, July ... neuroblastoma face long-term health and social problems, according to a ... who had been diagnosed with neuroblastoma -- a cancer that ... comparing it with data on 3,899 siblings of children with ...
    Cached Medicine News:Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 2Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 3Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 4Health News:AIDS patients face higher risk of HPV-related cancers as immunosuppression grows 2Health News:BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc. 2
    ... Launched in 1996, VISIPAQUE is the only isosmolar ... an osmolality equal to that of blood, VISIPAQUE ... is also the only contrast medium formulated with ... blood. In 1997, VISIPAQUE received FDA approval for ...
    The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
    Hand surgery basic instrument set...
    Castroviejo caliper...
    Medicine Products: